Download Files:
Cbl-b-IN-2
$970 – $5,000
Products Details
Product Description
– Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent[1].
Web ID
– HY-141431
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C29H30F5N5O2
References
– [1]Arthur T. Sands, et al. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus. Patent WO 2020210508A1.
CAS Number
– 2503325-21-9
Molecular Weight
– 575.57
Compound Purity
– 98.65
SMILES
– O=C1N(C2=CC=CC(C3(CC4=NN=CN4C)COC3)=C2)CC5=C1C=C(CN6C[C@@H](C)C(F)(F)CC6)C=C5C(F)(F)F
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : 140 mg/mL (ultrasonic)
Target
– E3 Ligase Ligand-Linker Conjugates
Pathway
– PROTAC
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
